Synthesis and Preclinical Evaluation of Radiolabeled [103Ru]BOLD-100

Author:

Happl Barbara123,Brandt Marie124ORCID,Balber Theresa124,Benčurová Katarína12ORCID,Talip Zeynep5ORCID,Voegele Alexander6,Heffeter Petra78ORCID,Kandioller Wolfgang38ORCID,Van der Meulen Nicholas P.56ORCID,Mitterhauser Markus1234,Hacker Marcus2ORCID,Keppler Bernhard K.38,Mindt Thomas L.1234ORCID

Affiliation:

1. Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria

2. Division of Nuclear Medicine, Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria

3. Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Strasse 42, 1090 Vienna, Austria

4. Joint Applied Medicinal Radiochemistry Facility, University of Vienna, Medical University of Vienna, 1090 Vienna, Austria

5. Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen, Switzerland

6. Laboratory of Radiochemistry, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen, Switzerland

7. Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8A, 1090 Vienna, Austria

8. Research Cluster “Translational Cancer Therapy Research”, Waehringer Strasse 42, 1090 Vienna, Austria

Abstract

The first-in-class ruthenium-based chemotherapeutic agent BOLD-100 (formerly IT-139, NKP-1339, KP1339) is currently the subject of clinical evaluation for the treatment of gastric, pancreatic, colorectal and bile duct cancer. A radiolabeled version of the compound could present a helpful diagnostic tool. Thus, this study investigated the pharmacokinetics of BOLD-100 in more detail to facilitate the stratification of patients for the therapy. The synthesis of [103Ru]BOLD-100, radiolabeled with carrier added (c.a.) ruthenium-103, was established and the product was characterized by HPLC and UV/Vis spectroscopy. In order to compare the radiolabeled and non-radioactive versions of BOLD-100, both complexes were fully evaluated in vitro and in vivo. The cytotoxicity of the compounds was determined in two colon carcinoma cell lines (HCT116 and CT26) and biodistribution studies were performed in Balb/c mice bearing CT26 allografts over a time period of 72 h post injection (p.i.). We report herein preclinical cytotoxicity and pharmacokinetic data for BOLD-100, which were found to be identical to those of its radiolabeled analog [103Ru]BOLD-100.

Funder

University of Vienna

Publisher

MDPI AG

Subject

Pharmaceutical Science

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3